Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice

Cancer Biology and Therapy

Volumn 15, Issue 9, 2014, Pages 1219-1225

  Bergantin, Elisa ^a   Quarta, Carmelo ^a   Nanni, Cristina ^a   Fanti, Stefano ^a   Pession, Andrea ^a   Cantelli Forti, Giorgio ^a   Tonelli, Roberto ^a   Hrelia, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alveolar; Combination therapy; Rhabdomyosarcoma; Sulforaphane; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; SULFORAFAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; ISOTHIOCYANATES; MICE, NUDE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC;

EID: 84906888011     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29684     Document Type: Article

References (25)

1. Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas Principles and practice of pediatric oncology. Eds: Pizzo PA, Poplack DG, 5th ed, Lippincott. 2006; 971-1002.
2. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002; 20:2672-9; PMID:12039929; http://dx.doi.org/10.1200/JCO.2002.03.137
3. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66:6936-46; PMID:16849537; http://dx.doi.org/10.1158/0008-5472. CAN-05-4578
4. rd. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15:1522-35; PMID:7862145
5. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006; 66:4742-9; PMID:16651427; http://dx.doi.org/10.1158/0008-5472.CAN-05-4292
6. Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, Purgato S, Missiaglia E, Tortori A, Renshaw J, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res 2012; 18:796-807; PMID:22065083; http://dx.doi.org/10. 1158/1078-0432.CCR-11-1981
7. Toffolatti L, Frascella E, Ninfo V, Gambini C, Forni M, Carli M, Rosolen A. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. J Pathol 2002; 196:450-8; PMID:11920742; http://dx.doi.org/10.1002/path.1068
8. Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res 2007; 635:90-104; PMID:17134937; http://dx.doi.org/10.1016/j. mrrev.2006.10.004
9. Bertl E, Bartsch H, Gerhäuser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 2006; 5:575-85; PMID:16546971; http://dx.doi.org/10.1158/1535-7163.MCT-05-0324
10. Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhäuser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276:32008-15; PMID:11410599; http://dx.doi.org/10. 1074/jbc.M104794200
11. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 2006; 20:506-8; PMID:16407454
12. Angeloni C, Leoncini E, Malaguti M, Angelini S, Hrelia P, Hrelia S. Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. J Agric Food Chem 2009; 57:5615-22; PMID:19456137; http://dx.doi.org/10.1021/jf900549c
13. Conaway CC, Yang YM, Chung FL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 2002; 3:233-55; PMID:12083319; http://dx.doi.org/10.2174/ 1389200023337496
14. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV, Herr I. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 2011; 19:188-95; PMID:20940707; http://dx.doi.org/10.1038/mt.2010.216
15. Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 2004; 15:5064-74; PMID:15356269; http://dx.doi.org/10.1091/mbc.E04-03-0184
16. Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ, Choi KS. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 2006; 66:1740-50; PMID:16452234; http://dx.doi.org/10.1158/0008-5472.CAN-05-1568
17. Nanni C, Di Leo K, Tonelli R, Pettinato C, Rubello D, Spinelli A, Trespidi S, Ambrosini V, Castellucci P, Farsad M, et al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur J Nucl Med Mol Imaging 2007; 34:755-62; PMID:17160412; http://dx.doi.org/10.1007/ s00259-006-0288-y
18. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007; 48:602-7; PMID:17401098; http://dx.doi.org/10.2967/jnumed.106.036608
19. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schäfer BW. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene 2010; 29:3942-52; PMID:20453878; http://dx.doi.org/10.1038/onc.2010.145
20. Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 2004; 3:1239-48; PMID:15486191
21. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 2004; 25:83-90; PMID:14514658; http://dx.doi.org/10.1093/carcin/bgg178
22. Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006; 55:53-62; PMID:16965241; http://dx.doi.org/10.1207/s15327914nc5501-7
23. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002; 1:97-104; PMID:12170781
24. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839-46; PMID:20458040; http://dx.doi.org/10.1200/JCO.2009.25.1991
25. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012; 11:3-13; PMID:22234808; http://dx.doi.org/10.1158/1535-7163.MCT-11-0434